InsiderStreet Equity Research

Produced by InsiderStreet.ai from live production data. It is not investment advice, not an offer or solicitation to buy or sell any security, and not a recommendation for any investor. Do not rely on it for any investment decision.

Last Close

$1257.03

2026-10-16

Market Cap

$1.18T

Volume

2.4M

52-Wk High

$1292.65

52-Wk Low

$783.85

Trailing PE

42.1

P/S

14.85

Gross Margin

83.4%

Net Margin

33.5%

ROE

93%

ROIC

31%

Piotroski

8/9

Altman Z

8.5

1-Yr Return

+53.6%

5-Yr Return

+1124.2%

Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to the research, development, and commercialization of human medicines across the world. Its therapeutic offerings include a comprehensive suite of diabetes medications. This encompasses various insulin formulations like Basaglar, the Humalog family (e.g., Mix 75/25, U-100, U-200, Mix 50/50), insulin lispro products (including protamine and mix 75/25), and the Humulin line (e.g., 70/30, N, R, U-500). Furthermore, Eli Lilly provides specialized treatments for type 2 diabetes, such as Jardiance, Trajenta, and Trulicity. In oncology, Eli Lilly offers a robust portfolio targeting various cancers. These include Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza, indicated for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal and various head and neck cancers; Retevmo, used in metastatic NSCLC, medullary thyroid, and other thyroid cancers; Tyvyt for relapsed or refractory classic Hodgkin's lymphoma and non-squamous NSCLC; and Verzenio, prescribed for HR+, HER2- metastatic breast cancer, node-positive, and early breast cancer. For autoimmune and inflammatory conditions, the company markets Olumiant for rheumatoid arthritis, and Taltz, which addresses plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Addressing neurological and pain management needs, Eli Lilly provides Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain. Emgality is available for migraine prevention and episodic cluster headaches, while Zyprexa treats schizophrenia, bipolar I disorder, and aids in bipolar maintenance. Other significant products include Bamlanivimab and etesevimab, along with Bebtelovimab, both developed for COVID-19. Cialis is offered for erectile dysfunction and benign prostatic hyperplasia, and Forteo is available for osteoporosis. Eli Lilly actively engages in strategic collaborations with numerous partners, including Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Established in 1876, Eli Lilly and Company maintains its corporate headquarters in Indianapolis, Indiana.

SectorHealthcareIndustryDrug Manufacturers - GeneralExchangeNYSEMarket Cap$1.18TEmployees50,000 (SEC-filed)CEODavid A. RicksIPO1972-06-01CountryUS

Lilly Corporate Center, Indianapolis, IN 46285 · Tel 317 276 2000 · lilly.com

INSIDERSTREET SCORE78 / 100Street mean $1342.90 (10 analysts, last qtr) — their number, not ours

INSIDER CONSENSUS SIGNALROUTINE SELLING — LOW SIGNAL$35M sold / 6 mo, zero open-market buys

1 Year vs S&P 500 · LLY +53.6% · S&P 500 +15.9% · spread +37.8pp

7 Years vs S&P 500 · LLY +1124.2% · S&P 500 +189.9% · spread +934.4pp

Both charts indexed to 100 at the start of their window and drawn on a single shared scale, so the gap to the benchmark is the gap you see. Adjusted closes throughout.

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

INSIDERSTREET
SCORE78of 100

Score Breakdown

Profitability	100/100
Growth	88/100
Momentum	94/100
Quality	84/100
Earnings Quality	67/100
Balance Sheet	54/100
Value	37/100
Risk (safety)	100/100
Overall	77.7/100

Each component is a diagnostic reading on its own 0-100 scale. The overall score is computed separately from the underlying financials and is not the average of the rows above — components are not equally weighted and three of them (Momentum, Value, Risk) are derived partly from price rather than from the business.

Peer Comparison — IS Score

Symbol	IS Score
JNJ	64
ABBV	67
MRK	49
NVS	65
AZN	71
AMGN	67
LLY	78

IS Score Trend — quarterly

14 quarters, 23 Q1 to 26 Q2. Peak 78 in 26 Q2, latest 78 — +0 since. Fell in 1 of the last 4 quarters. Dashed line marks 40 on the 0-100 scale.

BUSINESS QUALITY78 / 100IS Score 77.7 / 100 · +0.0 from peak of 78

Fundamental factor model, quarterly. Measures how the business is doing - not where the price is going.

PRICE STRUCTUREBULLISHTechnical Score 90 / 100 · Power +80 · 22 of 22 indicator votes bullish

Vote share across trend, momentum, volume, volatility and pattern families. Describes where the price is, not where it is going.

Both readings sit above the midpoint — business quality at 78 and price structure at 90 out of 100 — so they are not in conflict. The fundamentals and the tape are saying the same thing, which is the case in which either one alone would have been enough.

Trigger	Where it stands now	What it would mean
IS Score reaches 75 and holds two consecutive quarters	now 77.7	would move us up one band
IS Score stops falling - one quarter higher than the prior	last four: 72 → 73 → 73 → 78	the direction matters more than the level
Technical vote share back above 50%	now 100%	price structure no longer broken
Institutional holder count rises two quarters running	peak 4,653 → now 4,653	fewer institutions willing to hold is our clearest warning

We publish these so the view can be shown to be wrong. If none of them move and our reading does, we owe you an explanation.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

This page is InsiderStreet's own reading, produced from the data in the rest of this document. It is not a price target and not investment advice. Analyst consensus and street price targets appear later under their own heading and are the street's numbers, not ours.

Site Convergence Score3 of 4top 4% of 29,420 symbols

Sources Aligned— of 3independent disclosures

Congress (180d)5 buys2026-09-04

Insider Buys (180d)0none disclosed

ETF Funds (30d)2149 up / 1821 downnet +328 funds

Institutions Added (13F)262managers opening or increasing

Congressional and insider figures are disclosed purchases in the trailing 180 days; ETF figures are COUNTS OF FUNDS whose holding changed in 30 days, not dollars. Coincidence of separate disclosures, not coordination. An absent source means nothing qualifying was disclosed in its window.

Institutions holding — 12 quarters

Peak 4,653 · latest 4,653 (+0 from peak).

Quarter	Holders	13F shares	Value	Reported own%
2026 Q2	4,653	793.5M	$925.0B	88.9%
2026 Q1	4,391	776.4M	$694.3B	87.0%
2025 Q4	4,455	789.6M	$820.1B	88.5%
2025 Q3	3,906	765.3M	$569.1B	85.8%
2025 Q2	3,920	783.8M	$592.8B	87.8%
2025 Q1	3,932	836.6M	$669.5B	93.8%
2024 Q4	3,914	781.6M	$582.9B	87.6%
2024 Q3	3,669	790.1M	$665.0B	88.5%
2024 Q2	3,574	781.6M	$683.5B	87.6%
2024 Q1	3,471	782.7M	$586.9B	87.7%
2023 Q4	3,282	784.4M	$442.2B	87.9%
2023 Q3	2,982	785.8M	$408.2B	88.0%

How to read ownership above 100%. A 13F reports the positions a manager has investment discretion over, and where two or more managers share discretion over the same block, each one reports it. Summed across filers, the total can therefore exceed the shares actually outstanding without anything being wrong. We publish the figure as filed rather than netting it down, and flag separately any quarter where the arithmetic is not merely high but impossible.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Insider	Role	Date	Type	Shares	Value	Post-Txn Owned
Luciano Juan R	director	2026-09-21	A-Award	14	$0.02M	16,957
Fyrwald J Erik	director	2026-09-21	A-Award	9	$0.01M	75,536
Alvarez Ralph	director	2026-09-21	A-Award	11	$0.01M	55,838
Sulzberger Gabrielle	director	2026-09-21	A-Award	4	$0.00M	3,012
Seymour Melissa	EVP, Global Quality	2026-09-09	GIFT	12	—	1,038
Hernandez Edgardo	EVP & Pres., Mfg. Operations	2026-09-02	GIFT	13	—	46,083
Dozier Eric	EVP, Chief People Officer	2026-09-02	GIFT	216	—	14,239
Sulzberger Gabrielle	director	2026-08-17	A-Award	4	$0.00M	3,004

6-mo decomposition (Form 4)	Txns	Shares	Value	Signal weight
S — Open-market sales	6	31,828	$34.6M	Counted
M — Exercises (paired A/D)	1	981	—	None — mechanics
F — Tax withholding	1	439	$0.5M	None — compensation
G — Gifts	3	241	—	None
P — Open-market purchases	0	0	$0	Counted — none occurred

Monthly Net Insider Flow (000 shares)

Net of acquisitions minus dispositions, all Form 4 types.

Signal Summary

SignalRoutine Selling — Low Signal

Open-Market Sells$34.6M6 txns / 6 mo

Open-Market Buys$0.0M0 txns / 6 mo

ClusterNone active3+ insiders / 21 days

Filed	Filer	Shares registered	Est. proceeds
2026-10-15	Lilly Endowment, Inc.	305,000	$368.7M
2026-10-07	Lilly Endowment, Inc.	300,000	$347.2M
2026-08-17	Patrik Jonsson	6,500	$7.6M
2026-08-10	Donald Zakrowski	2,000	$2.4M
Trailing 12 mo	26 filings	6,298,000	$6233M

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Filed	Form	Reporting person	% of class	Shares
2026-07-23	SCHEDULE 13G/A	LILLY ENDOWMENT, INC.	9.60%	90.4M sh
2026-05-01	SCHEDULE 13G	Vanguard Capital Management	6.48%	61.3M sh
2026-04-20	SCHEDULE 13G/A	LILLY ENDOWMENT, INC.	9.70%	91.9M sh
2026-01-23	SCHEDULE 13G/A	LILLY ENDOWMENT, INC.	9.80%	92.2M sh

Member	Chamber	Trade	Size band	Traded	Disclosed
Ro Khanna	House	BUY	$1,001 - $15,000	2026-09-04	2026-10-09
Dan Newhouse	House	SELL	$1,001 - $15,000	2026-07-10	2026-07-20
Daniel Milton Newhouse	House	SELL	$1,001 - $15,000	2026-07-10	2026-07-20
Alan Armstrong	Senate	SELL	$1,001 - $15,000	2026-03-27	2026-07-20
Angus King	Senate	SELL	$1,001 - $15,000	2026-02-13	2026-03-24
Angus Stanley King	Senate	SELL	$1,001 - $15,000	2026-02-13	2026-03-24

House 12-Mo51 trades22 purchases

Senate 12-Mo22 trades12 purchases

CoverageSTOCK Act filings30-45 day disclosure lag

13F Filers (last complete Q)4,391

13F Shares776M87.0% of shares out

New / Closed242 / 228positions, QoQ

Increased / Reduced1,952 / 1,703positions, QoQ

Put/Call (13F)1.17option positions

Free Float90.1%848M sh

2.8 · Largest Reporting 13F Managers

Manager	Shares	Value
Sapient Capital Llc	1.5M	$1.7B
Assenagon Asset Management S.A.	784,936	$908M
Goelzer Investment Management, Inc	556,177	$644M
Private Capital Advisors, Inc.	411,540	$476M
Ninety One Uk Ltd	344,968	$399M
Fjarde Ap-Fonden /Fourth Swedish N	255,175	$295M

EDGAR 13F holdings as of 2026-09-30; filer values normalized to dollars.

2.9 · Top ETF & Fund Ownership

Fund	Weight	Position
VITSX	1.3%	$31.1B
VTSAX	1.3%	$31.1B
VTI	1.3%	$31.1B
VSMPX	1.3%	$31.1B
VOO	1.4%	$24.3B
VFFSX	1.4%	$24.3B

13F Filers Holding LLY — quarterly

Institutional Put/Call — quarterly

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Daily short-sale volume as % of volume reported in FINRA's short-sale file — a flow measure, not short interest; dashed = 50-day average.

Latest Session40.5%2026-10-15

20-Day Avg47.9%50-day 44.9%

TrendRising20d vs 50d

By Market CenterQ: 40% · N: 57% · B: 36%latest session

Weekly Notional ($B)

Where LLY Trades in the Dark

ATS Venue (4-wk)	Shares	Avg trade
Ubsa Ubs Ats	3.0M	28 sh
Incr Intelligent Cross Llc	2.9M	24 sh
Sgmt Sigma X2	1.7M	23 sh
Mlix Instinct X	1.3M	36 sh
Ebxl Level Ats	1.1M	14 sh
Mspl Ms Pool (Ats-4)	1.0M	83 sh

Where a dollar of Eli Lilly and Company revenue goes. All values FY2025 filings, live.

Region	Revenue	Share
UNITED STATES	$43.5B	67%
Europe	$11.6B	18%
Non-US	$6.1B	9%
JAPAN	$2.1B	3%
CHINA	$2.0B	3%

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

LLY (live moat model)Peer median: JNJ · ABBV · MRK · NVS · AZN

Component scores from the live moat model. Peer median illustrative.

Moat score 86/100 — Wide; primary source Efficient Scale.

3.8 · Employees (SEC filings)

Officer	Title
David A. Ricks	Chairman, Chief Executive Officer & President
Daniel Skovronsky	Chief Scientific & Product Officer and President of Lilly Research Laboratories
Anat Hakim	Executive Vice President, General Counsel & Secretary
Lucas E. Montarce	Executive Vice President & Chief Financial Officer

Revenue ($B)

EPS ($) — GAAP diluted actual, street-basis estimate

Actual bars are GAAP diluted EPS from the filed income statement; the lighter forward bars are street-basis consensus. The two are different measures and are not comparable quarter to quarter.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Quarterly EPS — Actual vs. Consensus

Beats (>2%)6 of 6recent quarters

Avg Surprise+16.9%

Next Report2026-10-29

Income Quality1.05OCF ÷ net income

Beat Rate—%0 of 0 quarters

Current Streak0longest 0

Avg EPS Surprise—%median —%

Surprise Trend—last 4 vs prior 4

Period	EPS est.	EPS actual	EPS surprise	Rev est. ($M)	Rev actual ($M)	Rev surprise

Announcement dates to . Consensus as it stood at each report. Revenue surprise shown where both estimate and actual are filed. A beat record is history, not a forecast.

Profit Margins (%)

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Revenue by Segment — Stacked

Live segmentation data.

YoY Growth Heatmap — Income Lines

YoY growth	FY21	FY22	FY23	FY24	FY25
Revenue	+15.4%	+0.8%	+19.6%	+32.0%	+44.7%
Gross profit	+10.2%	+4.3%	+23.4%	+35.4%	+49.1%
Operating income	+10.0%	+9.1%	+24.7%	+62.2%	+69.7%
Net income	-9.9%	+11.9%	-16.1%	+102.1%	+94.9%

$B · FY ends	FY21	FY22	FY23	FY24	FY25
Revenue	28.3	28.5	34.1	45.0	65.2
Cost of revenue	7.3	6.6	7.1	8.4	10.6
Gross profit	21.0	21.9	27.0	36.6	54.6
R&D expense	6.9	7.2	9.3	11.0	13.3
SG&A expense	6.1	6.1	6.9	8.1	11.1
Operating income	7.9	8.7	10.8	17.5	29.7
EBITDA	8.0	8.7	8.6	15.2	27.9
D&A	1.5	1.5	1.5	1.8	1.6
Pretax income	6.2	6.8	6.6	12.7	25.7
Income tax	0.6	0.6	1.3	2.1	5.1
Net income	5.6	6.2	5.2	10.6	20.6
Diluted EPS ($)	5.85	6.57	5.80	11.71	22.95
Diluted shares (M)	954	950	903	904	898

Operating CF$17B

CapEx$8B

Free cash flow$9B

SBC$1B

Buybacks$4B

Net cash change$4B

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Balance Sheet — Full

$B	FY22	FY23	FY24	FY25
Cash & equivalents	2.1	2.8	3.3	7.2
ST investments	0.1	0.1	0.2	0.1
Receivables (net)	8.6	11.3	13.3	20.2
Total current assets	18.0	25.7	32.7	55.6
PP&E (net)	10.1	12.9	17.1	24.7
Goodwill + intangibles	11.3	11.8	11.9	12.4
Total assets	49.5	64.0	78.7	112.5
Accounts payable	1.9	2.6	3.2	5.4
Short-term debt	1.5	6.9	5.1	1.6
Deferred revenue	0.0	0.0	0.0	0.0
Total current liabilities	17.1	27.3	28.4	35.2
Long-term debt	14.7	18.3	28.5	40.9
Total liabilities	38.7	53.1	64.4	85.9
Shareholders' equity	10.8	10.9	14.3	26.5

Cash Flow Statement — Full

$B	FY22	FY23	FY24	FY25
Net income	6.2	5.2	10.6	20.6
D&A	1.5	1.5	1.8	2.0
Stock-based compensation	0.4	0.6	0.6	0.6
Working capital change	(0.0)	(3.1)	(5.4)	(8.1)
Operating cash flow	7.6	4.2	8.8	16.8
Capital expenditures	(3.0)	(7.4)	(8.4)	(7.8)
Investing cash flow	(3.8)	(7.2)	(9.3)	(11.0)
Buybacks	(1.5)	(0.8)	(2.5)	(4.1)
Dividends paid	(3.5)	(4.1)	(4.7)	(5.4)
Debt issuance / (repay)	(0.1)	8.6	8.9	8.1
Financing cash flow	(5.4)	3.5	1.2	(2.2)
Free cash flow	4.6	(3.2)	0.4	9.0

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Balance Sheet Structure ($B)

Cash Generation vs Capex ($B)

Left: what the balance sheet is made of — the gap between the assets bar and the liabilities bar is book equity. Right: whether the capex bar is covered by the operating-cash bar; where it is not, the difference was funded externally and free cash flow goes negative.

Ratio	FY21	FY22	FY23	FY24	FY25	TTM
PROFITABILITY
ROE	76.4%	63.6%	48.9%	84.8%	101.3%	93%
ROA	11.7%	12.7%	9.2%	14.8%	21.6%	18.8%
ROIC	32.5%	32.2%	26.1%	32.9%	38.6%	31.0%
Gross margin	74.2%	76.8%	79.2%	81.3%	83.8%	83.4%
Operating margin	28.0%	30.3%	31.6%	38.9%	45.6%	49.7%
Net margin	19.7%	21.9%	15.4%	23.5%	31.7%	33.5%
EBITDA margin	28.4%	30.3%	25.1%	33.8%	42.9%	54.4%
FCF margin	19.0%	16.1%	-9.2%	1.1%	13.8%	—
VALUATION
P/E	45.46	54.36	99.16	65.35	46.76	42.1
P/B	28.26	31.87	48.24	48.77	36.37	33.1
P/S	8.96	11.89	15.23	15.36	14.81	14.85
P/FCF	47.10	73.79	-164.86	1354.90	107.56	59.0
EV/EBITDA	33.17	40.82	63.25	47.43	35.81	28.4
EV/Revenue	9.42	12.38	15.88	16.04	15.35	15.4
Earnings yield	2.2%	1.8%	1.0%	1.5%	2.1%	2.38%
FCF yield	2.1%	1.4%	-0.6%	0.1%	0.9%	1.69%

Ratio	FY21	FY22	FY23	FY24	FY25	TTM
LEVERAGE & SOLVENCY
Current ratio	1.23	1.05	0.94	1.15	1.58	1.35
Quick ratio	0.97	0.80	0.73	0.89	1.19	1.00
Debt / equity	1.88	1.52	2.34	2.37	1.60	1.62
Debt / assets	34.6%	32.8%	39.4%	42.7%	37.8%	38.6%
Net debt / EBITDA	1.61	1.62	2.60	1.98	1.26	1.06
Interest coverage	19.12	21.53	14.49	17.24	33.16	—

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Ratio	FY21	FY22	FY23	FY24	FY25	TTM
EFFICIENCY
Asset turnover	0.59	0.58	0.60	0.63	0.68	0.56
Receivables turnover	4.51	4.21	4.27	4.48	4.53	3.4
DSO (days)	81	87	85	81	81	108
DPO (days)	82	99	117	126	149	169
Cash conversion cycle	195	213	229	245	300	402
GROWTH (YoY)
Revenue growth	15.4%	0.8%	19.6%	32.0%	44.7%	—
Net income growth	-9.9%	11.9%	-16.1%	102.1%	94.9%	—
EPS growth	-9.6%	12.3%	-11.8%	102.3%	96.0%	—
FCF growth	20.2%	-14.6%	-168.5%	116.2%	1656.5%	—
PER SHARE ($)
EPS (diluted, TTM)	5.85	6.57	5.80	11.73	22.98	29.93
Book value / share	9.42	11.21	11.92	15.71	29.55	37.96
Revenue / share	29.69	30.04	37.75	49.87	72.58	89.27
FCF / share	5.65	4.84	-3.49	0.57	9.99	22.47
Cash / share	4.10	2.33	3.24	3.79	8.09	10.03
SHAREHOLDER RETURN & SCORES
Buyback yield	0.5%	0.4%	0.1%	0.4%	0.4%	0.58%
Altman Z-Score	5.20	6.62	6.96	7.89	8.61	8.5
Piotroski F-Score	6	8	5	7	8	8/9
Beneish M-Score	-2.45	-2.59	-2.08	-2.11	-1.89	-2.01

Model	Score	Zone	Note
Piotroski F-Score	8 / 9	Strong
Altman Z-Score	8.5	Safe (>2.99)	Safe
Income quality	1.05	Cash-backed	OCF ÷ net income
Beneish M-Score	-2.01	Elevated	vs −2.22 threshold

DuPont Decomposition (TTM)	Value
Tax burden	0.80
Interest burden	0.89
Operating margin	47.6%
Asset turnover	0.66×
Financial leverage	4.66×
= ROE	102%

Growth Quality (live)	Value
Revenue stability	0.79
Earnings stability	0.69
Earnings persistence	0.50
Revenue CAGR 3y	39.2%
EPS CAGR 3y	63.4%
FCF CAGR 3y	84.1%

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Buyback Yield0.58%

Dividend Yield0.53%

Total Shareholder Return1.12%cash yield

SBC / Revenue0.8%dilution pressure

Company	Mkt cap	P/E	ROE	Net margin	Rev growth	Piotroski	1-yr ret
JNJ	$615.9B	38.7	26%	21.9%	+8.1%	7/9	+33.9%
ABBV	$504.4B	80.4	-206%	21.3%	+10.4%	7/9	+25.8%
MRK	$360.1B	115.8	7%	-8.0%	+4.5%	4/9	+75.4%
NVS	$286.3B	22.9	31%	22.7%	+0.8%	5/9	+15.1%
AZN	$256.5B	24.7	22%	16.3%	+8.6%	9/9	—
AMGN	$233.8B	26.7	91%	23.6%	+9.2%	8/9	—
GILD	$193.7B	-60.1	-21%	—	+5.5%	5/9	—
PFE	$168.6B	39.1	5%	-1.6%	-0.2%	7/9	—

1-yr returns computed from adjusted price history; peers without a tracked series show —.

Buy

45 Analysts

Str Sell (0)Sell (3)Hold (9)Buy (33)Str Buy (0)

Mean Target (qtr)$1342.9010 targets

Target vs. Price+6.8%last-quarter mean

Next Report2026-10-29street $5.65

Consensus estimates	Revenue mean	High / Low	EPS mean	High / Low	# EPS est.
FY2026	$88.74B	$91.42B / $87.11B	$34.97	$37.56 / $32.88	16
FY2027	$102.67B	$105.14B / $98.09B	$47.35	$50.67 / $44.10	16
FY2028	$114.85B	$129.06B / $102.48B	$54.14	$63.66 / $47.01	11

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Street Price Target — Trajectory

Window	Avg Target	vs. Price	# Targets
Last Month	$1435.00	+14.2%	2
Last Quarter	$1342.90	+6.8%	10
Last Year	$1275.04	+1.4%	54
All Time	$890.68	-29.1%	134

Rolling mean of published targets vs. last close $1257.03. Aggregated from StreetInsider, Benzinga, Pulse 2.0.

Third-Party Composite Rating

B

DCF

3/5

ROE

5/5

ROA

5/5

Debt/Eq

1/5

P/E

1/5

P/B

1/5

Independent quant composite as of 2026-10-16; components scored 1–5 (5 best). Shown for contrast with the InsiderStreet Score — methodologies differ.

LLY +53.6% vs S&P 500 +15.9% — spread +37.8pp

Sector — XLV +24.2%

Peer Set — indexed to 100

All series indexed to 100 at the start of the window, adjusted closes.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Candlesticks with SMA 20/50 overlay, Bollinger (20,2σ) band, volume, and Wilder RSI(14) — computed from live daily OHLCV.

Moving Average	Value	Distance	% Distance	Signal
SMA 20	$1178.76	+78.27	+6.64%	Above
SMA 50	$1180.17	+76.86	+6.51%	Above
SMA 200	$1079.47	+177.56	+16.45%	Above
EMA 9	$1205.28	+51.75	+4.29%	Above
EMA 21	$1184.94	+72.09	+6.08%	Above
EMA 50	$1172.97	+84.06	+7.17%	Above
EMA 200	$1085.43	+171.60	+15.81%	Above

Series and readings from the nightly technical-indicator history — identical data to the site's ribbon chart. Supertrend segments colored by direction.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

TECHNICAL VERDICTBULLISHPower Score +8022 of 22 indicator votes bullish

Family Scores (site weights)

Trend 30%100

Momentum 25%100

Volume 20%88

Volatility 10%100

Patterns 15%50

This Week100% bullishof 11 price-based votes

4 Weeks Ago36%+64 pts since

12 Weeks Ago45%+55 pts since

ReadImprovingweek-over-week trajectory

Price vs SMA 20$1178.76

Price vs SMA 50$1180.17

Price vs SMA 200$1079.47

EMA 9/21 Cross1205.3/1184.9

SMA 50/200Golden

ADX DirectionADX 23

Supertrend$1153

Parabolic SAR$1139

SMA Slope5.200

RSI68.6

Stochastic K/D87/75

StochRSI K/D100/86

Williams %R-13

CCI277

TSI vs Signal15.9

CMO37.1

ROC9.99%

OBV SignalAccum

Chaikin MF0.020

MFI57

Force Index34M

Elder Ray Bull89.62

RSI (14)30 oversold · 70 overbought

Stochastic %Kvs %D 75

Money Flowvolume-weighted RSI

ADXtrend strength · <20 weak

Williams %Rinverted scale

Level	Value	Level	Value
Pivot / R1 / R2	$1252.72 / $1274.77 / $1297.94	S1 / S2	$1229.55 / $1207.50
Bollinger (20,2)	$1118.53 – $1238.99	Squeeze	Off
52-wk range	$782.70 – $1292.65	Off 52-wk high	-2.8%
ATR (14)	$35.80 (2.8%)	Historical vol	26.6%

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

+1.3%Jan50%

-0.0%Feb45%

+2.1%Mar67%

+1.7%Apr55%

+1.8%May60%

+3.1%Jun70%

+0.6%Jul50%

+1.8%Aug55%

+0.5%Sep60%

-1.3%Oct50%

+3.3%Nov75%

+4.1%Dec60%

Sample: 20 years — treat short histories as suggestive, not statistical.

Computed from live weekly prices	LLY	S&P 500
Weekly volatility (σ, 1y)	4.50%	1.83%
Best / worst week (1y)	+11.0% / -8.3%	—
Max drawdown (5y, monthly)	-24.5%	—
1-week VaR (95%)	-6.5%	—
Beta (5y)	0.50	1.00

LLY EQUITY WEATHER (LIVE)PARTLY CLOUDY · +26

Trend+43

Momentum+67

Volume+42

Volatility-60

Breadth-30

MARKET REGIME (2026-10-16)NEUTRAL

VIX19.99Normal

Dow TheoryConfirmed Bearish

SPY / QQQ TSI7.2 / 4.7trend strength

Sector Strength46/100breadth average

Average sentiment of 1,551 stories, weekly buckets, −1 to +1.

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Overall+26.0+35.5 vs industry

Trend+43.0+47.0 vs industry

Momentum+67.0+57.1 vs industry

Volume+42.1+25.5 vs industry

Reading	LLY	Drug Manufacturers - General n=150	Healthcare n=5,272	All US symbols n=70,435
Overall	+26.0	-9.5	-24.0	-20.5
Trend	+43.0	-4.1	-25.6	-21.3
Momentum	+67.0	+9.9	-28.5	-15.8
Volume	+42.1	+16.6	-25.0	-3.8

Trend, momentum and volume are computed per company. Volatility and breadth are market-regime values shared by every symbol in the universe, so they are reported once under Market Regime rather than compared here - a company cannot differ from its sector on a constant.

Executive	Total comp	Structure
David A. Ricks Chair, President, and Chief E	$36.7M	81% equity+incentive
Daniel M. Skovronsky, M.D., Ph.D. Executive	$17.8M	86% equity+incentive
Anat Hakim Executive Vice President, General	$9.8M	83% equity+incentive
Lucas Montarce Executive Vice President and	$8.5M	85% equity+incentive
Jake Van Naarden Executive Vice President an	$7.6M	86% equity+incentive

Pillar (live disclosure scores)	Score
Environmental	80
Social	63
Governance	69
Composite ESG	71

Composite ESG Trend

Filed	8-K contents	Items
2026-08-05	Earnings Release; Exhibits	2.02,9.01
2026-05-20	Other Events; Exhibits	8.01,9.01
2026-05-07	Shareholder Vote	5.07
2026-04-30	Earnings Release; Exhibits	2.02,9.01
2026-02-04	Results of Operations and Financial Condition; Financial Statements an	2.02,9.01
2025-11-21	Departure/Election of Directors; Appointment of Officers	5.02
2025-10-30	Results of Operations and Financial Condition; Financial Statements an	2.02,9.01
2025-08-20	Other Events; Financial Statements and Exhibits	8.01,9.01

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Methodology. Every figure originates in InsiderStreet's production data layer and is computed deterministically by the same engines that power insiderstreet.ai. This factsheet contains no model-written text. Sections without underlying data are omitted rather than estimated.

DISCLOSURES. This document is produced by InsiderStreet.ai from live production data. It is not investment advice, not an offer or solicitation to buy or sell any security, and not a recommendation tailored to any person. Data is sourced as of the dates shown and may no longer be current. InsiderStreet.ai is not a registered investment adviser or broker-dealer. Investing involves risk, including loss of principal. Past performance does not guarantee future results. Do not make any investment decision based on this document. © 2026 InsiderStreet.ai — all rights reserved. Redistribution prohibited.

Data domain	Source	Coverage for this report
Price & volume	market_db.historical_prices	52 rows
Fundamentals	income_statements_annual	6 rows · 2020 to 2025
Reported vs consensus	fact/earnings_calendar	24 rows · 2020-10-27 to 2026-08-05
Analyst estimates	dim/forward_estimates	3 rows · 2026-12-31 to 2028-12-31
Institutional ownership (13F)	holdings_db.institutional_ownership_summary	121 rows · 1987 to 2026
Insider transactions (Form 4)	edgar/form4	12 rows · 2026-08-17 to 2026-09-21
Proposed sales (Form 144)	edgar/form144	1 record
Beneficial ownership (13D/G)	edgar/13dg	4 rows · 2026-01-23 to 2026-07-23
Short-sale volume (FINRA)	edgar/short_volume_daily	60 rows · 2026-07-23 to 2026-10-15
Dark pool (ATS, tier 1)	edgar/darkpool_weekly	12 rows · 2026-06-15 to 2026-08-31
ETF & fund holding	etf_holdings_changelog (30d)	1 record
Peer set	stock_peers_dynamic	8 rows
Industry medians	industry_medians	1 record
Congressional trades	congress_db (House + Senate)	1 record
ESG	fact/esg_disclosures	1 record

Method. Every figure in this factsheet is looked up from a named field computed in code. It contains no model-written text.

Not covered. Short interest as a percent of float and days-to-cover are not in this data set — the short-sale figures above are FINRA volume, a flow, and cannot support squeeze or covering analysis. Options positioning and intraday data are also absent. 13F ownership is filed 45 days after quarter end and congressional trades are disclosed on a lag, so both describe a past position, not a current one.

Eli Lilly and Company (LLY)

Eli Lilly and Company (LLY)

Score Breakdown

Peer Comparison — IS Score

IS Score Trend — quarterly

Eli Lilly and Company (LLY)

Institutions holding — 12 quarters

Eli Lilly and Company (LLY)

Monthly Net Insider Flow (000 shares)

Signal Summary

Eli Lilly and Company (LLY)

2.8 · Largest Reporting 13F Managers

2.9 · Top ETF & Fund Ownership

13F Filers Holding LLY — quarterly

Institutional Put/Call — quarterly

Eli Lilly and Company (LLY)

Where LLY Trades in the Dark

Eli Lilly and Company (LLY)

3.8 · Employees (SEC filings)

Eli Lilly and Company (LLY)

Eli Lilly and Company (LLY)

Eli Lilly and Company (LLY)

Balance Sheet — Full

Cash Flow Statement — Full

Eli Lilly and Company (LLY)

Eli Lilly and Company (LLY)

Eli Lilly and Company (LLY)

Eli Lilly and Company (LLY)

Street Price Target — Trajectory

Third-Party Composite Rating

Eli Lilly and Company (LLY)

Eli Lilly and Company (LLY)

Family Scores (site weights)

Eli Lilly and Company (LLY)

Eli Lilly and Company (LLY)

Eli Lilly and Company (LLY)